Article
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
The Lancet. Oncology - 1 Sept 2020
Subbiah Vivek, Lassen Ulrik, Élez Elena, Italiano Antoine, Curigliano Giuseppe, Javle Milind, de Braud Filippo, Prager Gerald W, Greil Richard, Stein Alexander, Fasolo Angelica, Schellens Jan H M, Wen Patrick Y, Viele Kert, Boran Aislyn D, Gasal Eduard, Burgess Paul, Ilankumaran Palanichamy, Wainberg Zev A
Abstract excerpt
BACKGROUND: Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The combination of dabrafenib and trametinib has shown activity in several BRAFV600E-mutated cancers. We aimed to assess the activity and safety of dabrafenib and trametinib combination therapy in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.